Structural irregularities in MR corpus callosal images and their association with cerebrospinal fluid biomarkers in Mild Cognitive Impairments

被引:2
|
作者
Shaji, Sreelakshmi [1 ]
Palanisamy, Rohini [2 ]
Swaminathan, Ramakrishnan [1 ]
机构
[1] Indian Inst Technol Madras, Dept Appl Mech, Biomed Engn Grp, Noninvas Imaging & Diagnost Lab, Chennai, India
[2] Indian Inst Informat Technol Design & Mfg, Chennai, India
关键词
Early Mild Cognitive Impairment; Corpus Callosum; Structural irregularity; Fourier analysis; Cerebrospinal fluid markers; ALZHEIMERS-DISEASE; CSF BIOMARKERS;
D O I
10.1016/j.neulet.2023.137329
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
In this study, irregularity measures from MR images of corpus callosal brain structures in healthy and Mild Cognitive Impairment (MCI) conditions are extracted and their association with Cerebrospinal Fluid (CSF) biomarkers are analyzed. For this, MR images of healthy controls, Early MCI (EMCI) and Late MCI (LMCI) subjects are considered from a public database. The considered images are preprocessed and corpus callosal structure is segmented. Structural irregularity measures are extracted from the segmented regions using Fourier analysis. Statistical tests are performed to identify the significant features which can characterize the MCI stages. Association of these measures with CSF amyloid beta and tau concentrations are further investigated. Results demonstrate that Fourier spectral analysis is able to characterize the non-periodic variations in the corpus callosal structures of healthy, EMCI and LMCI MR images. The callosal irregularity measures increase as the disease progresses from healthy to LMCI. Phosphorylated tau concentrations in CSF demonstrate a positive correlation with irregularity measures across the diagnostic groups. Significant association of callosal measures and amyloid beta levels are found to be absent in MCI stages. As corpus callosal structural irregularities due to early MCI condition and their association with CSF markers remain uncharacterized in the literature, this study seems to be clinically significant for the timely intervention of pre-symptomatic MCI stages.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment
    Sierra-Rion, Alba
    Balasa, Mircea
    Olives, Jaume
    Antonell, Anna
    Iranzo, Alex
    Castellvi, Magda
    Bosch, Beatriz
    Grau-Rivera, Oriol
    Fernandez-Villullas, Guadalupe
    Rami, Lorena
    Llado, Albert
    Sanchez-Valle, Raquel
    Luis Molinuevo, Jose
    NEURODEGENERATIVE DISEASES, 2016, 16 (1-2) : 69 - 76
  • [22] Association between cerebrospinal fluid clusterin and biomarkers of Alzheimer's disease pathology in mild cognitive impairment: a longitudinal cohort study
    Wang, Hao
    Ma, Ling-Zhi
    Sheng, Ze-Hu
    Liu, Jia-Yao
    Yuan, Wei-Yu
    Guo, Fan
    Zhang, Wei
    Tan, Lan
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [23] Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment
    Garrett, Stephanie L.
    McDaniel, Darius
    Obideen, Malik
    Trammell, Antoine R.
    Shaw, Leslie M.
    Goldstein, Felicia C.
    Hajjar, Ihab
    JAMA NETWORK OPEN, 2019, 2 (12)
  • [24] Cerebrospinal fluid routine parameters and biomarkers as potential indicators of clinical progression in mild cognitive impairment
    Nielsen, M. Schjonning
    Hogh, P.
    Hasselbalch, S.
    Simonsen, A. Hviid
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 686 - 686
  • [25] Combination of Hippocampal Volume and Cerebrospinal Fluid Biomarkers Improves Predictive Value in Mild Cognitive Impairment
    Eckerstrom, C.
    Andreasson, U.
    Olsson, E.
    Rolstad, S.
    Blennow, K.
    Zetterberg, H.
    Malmgren, H.
    Edman, A.
    Wallin, A.
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2010, 29 (04) : 294 - 300
  • [26] Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis
    Michaud, Tzeyu L.
    Kane, Robert L.
    McCarten, J. Riley
    Gaugler, Joseph E.
    Nyman, John A.
    Kuntz, Karen M.
    JOURNAL OF ALZHEIMERS DISEASE, 2015, 47 (03) : 729 - 740
  • [27] Cerebrospinal Fluid Biomarkers for the Diagnosis of Prodromal Alzheimer's Disease in Amnestic Mild Cognitive Impairment
    Park, Jung Eun
    Choi, Kyu Yeong
    Kim, Byeong C.
    Choi, Seong-Min
    Song, Min-Kyung
    Lee, Jang Jae
    Kim, Jahae
    Song, Ho-Chun
    Kim, Hoo-Won
    Ha, Jung-Min
    Seo, Eun Hyun
    Song, Woo Keun
    Park, Sung-Gyoo
    Lee, Jung Sup
    Lee, Kun Ho
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA, 2019, 9 (01): : 100 - 113
  • [28] Use of Cerebrospinal Fluid Biomarkers for Diagnosis of Incipient Alzheimer Disease in Patients with Mild Cognitive Impairment
    Dean, Robert A.
    Shaw, Leslie M.
    CLINICAL CHEMISTRY, 2010, 56 (01) : 7 - 9
  • [29] Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment
    Herukka, Sanna-Kaisa
    Simonsen, Anja Hviid
    Andreasen, Niels
    Baldeiras, Ines
    Bjerke, Maria
    Blennow, Kaj
    Engelborghs, Sebastiaan
    Frisoni, Giovanni B.
    Gabryelewicz, Tomasz
    Galluzzi, Samantha
    Handels, Ron
    Kramberger, Milica G.
    Kulczynska, Agnieszka
    Luis Molinuevo, Jose
    Mroczko, Barbara
    Nordberg, Agneta
    Oliveira, Catarina Resende
    Otto, Markus
    Rinne, Juha O.
    Rot, Uros
    Saka, Esen
    Soininen, Hilkka
    Struyfs, Hanne
    Suardi, Silvia
    Visser, Pieter Jelle
    Winblad, Bengt
    Zetterberg, Henrik
    Waldemar, Gunhild
    ALZHEIMERS & DEMENTIA, 2017, 13 (03) : 285 - 295
  • [30] Longitudinal changes of cerebrospinal fluid biomarkers in patients with Alzheimer's disease and mild cognitive impairment
    Uspenskaya, O.
    Heinzel, S.
    Teipel, S. J.
    Hampel, H.
    Buerger, K.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 171 - 172